Tibotec BVBA, Mechelen, Belgium.
AIDS. 2010 Mar 27;24(6):921-4. doi: 10.1097/QAD.0b013e328336ac2a.
Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint.
依曲韦林是一种最近获得批准的非核苷类逆转录酶抑制剂。在 DUET 三期临床试验中，对有病毒学反弹的经治患者亚组进行了研究，评估了依曲韦林限制对蛋白酶抑制剂（特别是达芦那韦）耐药性出现的能力。在出现反弹的患者中，与接受安慰剂治疗的患者相比，接受依曲韦林治疗的患者发生与蛋白酶抑制剂总体耐药性和达芦那韦耐药性相关的突变较少，而在依曲韦林组中，与安慰剂组相比，更多的患者在终点时保持基线达芦那韦敏感性。
